Miniatura

Fitxers

jcm-13-02596.pdf (918.13 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2024-04-28

Llicència de publicació

cc by (c) Vazirani, Ravi et al., 2024
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/214568

Elevated Troponins after COVID-19 Hospitalization and Long-Term COVID-19 Symptoms: Incidence, Prognosis, and Clinical Outcomes—Results from a Multi-Center International Prospective Registry (HOPE-2)

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3390/jcm13092596

Resum

Background: Acute cardiac injury (ACI) after COVID-19 has been linked with unfavorable clinical outcomes, but data on the clinical impact of elevated cardiac troponin on discharge during follow-up are scarce. Our objective is to elucidate the clinical outcome of patients with elevated troponin on discharge after surviving a COVID-19 hospitalization. Methods: We conducted an analysis in the prospective registry HOPE-2 (NCT04778020). Only patients discharged alive were selected for analysis, and all-cause death on follow-up was considered as the primary endpoint. As a secondary endpoint, we established any long-term COVID-19 symptoms. HOPE-2 stopped enrolling patients on 31 December 2021, with 9299 patients hospitalized with COVID-19, of which 1805 were deceased during the acute phase. Finally, 2382 patients alive on discharge underwent propensity score matching by relevant baseline variables in a 1:3 fashion, from 56 centers in 8 countries. Results: Patients with elevated troponin experienced significantly higher all-cause death during follow-up (log-rank = 27.23, p < 0.001), and had a higher chance of experiencing long-term COVID-19 cardiovascular symptoms. Specifically, fatigue and dyspnea (57.7% and 62.8%, with p-values of 0.009 and <0.001, respectively) are among the most common. Conclusions: After surviving the acute phase, patients with elevated troponin on discharge present increased mortality and long-term COVID-19 symptoms over time, which is clinically relevant in follow-up visits.

Matèries

COVID-19, Miocardiopaties

Matèries (anglès)

COVID-19, Myocardiopathies

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

VAZIRANI, Ravi, FELTES, Gisela, SÁNCHEZ DEL HOYO, Rafael, VIANA LLAMAS, María c., RAPOSEIRAS ROUBÍN, Sergio, ROMERO, Rodolfo, ALFONSO RODRÍGUEZ, Emilio, URIBARRI, Aitor, SANTORO, Francesco, BECERRA MUÑOZ, Víctor, PEPE, Martino, CASTRO MEJÍA, Alex f., SIGNES COSTA, Jaime, GONZALEZ, Adelina, MARÍN, Francisco, LOPEZ PAÍS, Javier, CERRATO, Enrico, VÁZQUEZ CANCELA, Olalla, ESPEJO PAERES, Carolina, LÓPEZ MASJUAN, Álvaro, VELICKI, Lazar, EL-BATTRAWY, Ibrahim, RAMAKRISHNA, Harish, FERNANDEZ ORTIZ, Antonio, NUÑEZ GIL, Ivan j.. Elevated Troponins after COVID-19 Hospitalization and Long-Term COVID-19 Symptoms: Incidence, Prognosis, and Clinical Outcomes—Results from a Multi-Center International Prospective Registry (HOPE-2). _Journal of Clinical Medicine_. 2024. Vol. 13, núm. 9, pàgs. 2596. [consulta: 10 de gener de 2026]. ISSN: 2077-0383. [Disponible a: https://hdl.handle.net/2445/214568]

Exportar metadades

JSON - METS

Compartir registre